Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study

Emanuela Cova,1 Laura Pandolfi,1 Miriam Colombo,2 Vanessa Frangipane,1 Simona Inghilleri,1 Monica Morosini,1 Simona Mrakic-Sposta,3 Sarah Moretti,3 Manuela Monti,4 Ymera Pignochino,5 Silvia Benvenuti,5 Davide Prosperi,2,6 Giulia Stella,1 Patrizia Morbini,7 Federica Meloni8 1Clinic of Lung Diseases,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cova E, Pandolfi L, Colombo M, Frangipane V, Inghilleri S, Morosini M, Mrakic-Sposta S, Moretti S, Monti M, Pignochino Y, Benvenuti S, Prosperi D, Stella G, Morbini P, Meloni F
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://doaj.org/article/0f3cb39b00e94184981238b22cad5483
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:0f3cb39b00e94184981238b22cad5483
record_format dspace
institution DOAJ
collection DOAJ
language EN
topic Gold nanoparticles
nano-drug delivery
mesothelioma
pemetrexed
intrapleural delivery
Medicine (General)
R5-920
spellingShingle Gold nanoparticles
nano-drug delivery
mesothelioma
pemetrexed
intrapleural delivery
Medicine (General)
R5-920
Cova E
Pandolfi L
Colombo M
Frangipane V
Inghilleri S
Morosini M
Mrakic-Sposta S
Moretti S
Monti M
Pignochino Y
Benvenuti S
Prosperi D
Stella G
Morbini P
Meloni F
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
description Emanuela Cova,1 Laura Pandolfi,1 Miriam Colombo,2 Vanessa Frangipane,1 Simona Inghilleri,1 Monica Morosini,1 Simona Mrakic-Sposta,3 Sarah Moretti,3 Manuela Monti,4 Ymera Pignochino,5 Silvia Benvenuti,5 Davide Prosperi,2,6 Giulia Stella,1 Patrizia Morbini,7 Federica Meloni8 1Clinic of Lung Diseases, IRCCS Foundation Policlinico San Matteo, Pavia, Italy; 2Deparment of Biotechnology and Bioscience, University of Milano - Bicocca, Milan, Italy; 3National Council of Research, Institute of Bioimaging and Molecular Physiology, Segrate, Milan, Italy; 4Laboratory of Biotechnology, Research Center of Rigenerative Medicine, IRCCS Foundation Policlinico San Matteo, Pavia, Italy; 5Experimental Clinical Molecular Oncology, IRCCS Candiolo Cancer Institute-FPO, Candiolo, Turin, Italy; 6Laboratory of Nanomedicine, Clinical Institute of Maugeri, S.p.A., Pavia, Italy; 7Department of Molecular Medicine, Pathology Unit, IRCCS Foundation Policlinico San Matteo, Pavia, Italy; 8Department of Internal Medicine, Pneumology Unit, University of Pavia, Pavia, Italy Purpose: Malignant pleural mesothelioma (MPM) is an aggressive tumor characterized by poor prognosis. Its incidence is steadily increasing due to widespread asbestos exposure. There is still no effective therapy for MPM. Pemetrexed (Pe) is one of the few chemotherapeutic agents approved for advanced-stage disease, although the objective response to the drug is limited. The use of gold nanoparticles (GNPs) as a drug delivery system promises several advantages, including specific targeting of malignant cells, with increased intracellular drug accumulation and reduced systemic toxicity, and, in the case of MPM, direct treatment administration into the pleural space. This study aims at exploring CD146 as a potential MPM cell-specific target for engineered Pe-loaded GNPs and to assess their effectiveness in inhibiting MPM cell line growth.Methods: MPM cell lines and primary cultures obtained by pleural effusions from MPM patients were assayed for CD146 expression by flow cytometry. Internalization by MPM cell lines of fluorescent dye-marked GNPs decorated with a monoclonal anti CD146 coated GNPs (GNP-HC) was proven by confocal microscopy. The effects of anti CD146 coated GNPs loaded with Pe (GNP-HCPe) on MPM cell lines were evaluated by cell cycle (flow cytometry), viability (MTT test), clonogenic capacity (soft agar assay), ROS production (electric paramagnetic resonance), motility (wound healing assay), and apoptosis (flow cytometry).Results: GNP-HC were selectively uptaken by MPM cells within 1 hour. MPM cell lines were blocked in the S cell cycle phase in the presence of GNP-HCPe. Both cell viability and motility were significantly affected by nanoparticle treatment compared to Pe. Apoptotic rate and ROS production were significantly higher in the presence of nanoparticles. Clonogenic capacity was completely inhibited following nanoparticle internalization.Conclusion: GNP-HCPe treatment displays in vitro antineoplastic action and is more effective than Pe alone in inhibiting MPM cell line malignant phenotype. The innovative use of specifically targeted GNPs opens the perspective of local intrapleural administration to avoid normal cell toxicity and enhance chemotherapy efficacy. Keywords: gold nanoparticles, nanodrug delivery, mesothelioma, pemetrexed, intrapleural delivery
format article
author Cova E
Pandolfi L
Colombo M
Frangipane V
Inghilleri S
Morosini M
Mrakic-Sposta S
Moretti S
Monti M
Pignochino Y
Benvenuti S
Prosperi D
Stella G
Morbini P
Meloni F
author_facet Cova E
Pandolfi L
Colombo M
Frangipane V
Inghilleri S
Morosini M
Mrakic-Sposta S
Moretti S
Monti M
Pignochino Y
Benvenuti S
Prosperi D
Stella G
Morbini P
Meloni F
author_sort Cova E
title Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
title_short Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
title_full Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
title_fullStr Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
title_full_unstemmed Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
title_sort pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
publisher Dove Medical Press
publishDate 2019
url https://doaj.org/article/0f3cb39b00e94184981238b22cad5483
work_keys_str_mv AT covae pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy
AT pandolfil pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy
AT colombom pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy
AT frangipanev pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy
AT inghilleris pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy
AT morosinim pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy
AT mrakicspostas pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy
AT morettis pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy
AT montim pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy
AT pignochinoy pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy
AT benvenutis pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy
AT prosperid pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy
AT stellag pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy
AT morbinip pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy
AT melonif pemetrexedloadednanoparticlestargetedtomalignantpleuralmesotheliomacellsaninvitrostudy
_version_ 1718399616039256064
spelling oai:doaj.org-article:0f3cb39b00e94184981238b22cad54832021-12-02T07:03:54ZPemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study1178-2013https://doaj.org/article/0f3cb39b00e94184981238b22cad54832019-01-01T00:00:00Zhttps://www.dovepress.com/pemetrexed-loaded-nanoparticles-targeted-to-malignant-pleural-mesothel-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Emanuela Cova,1 Laura Pandolfi,1 Miriam Colombo,2 Vanessa Frangipane,1 Simona Inghilleri,1 Monica Morosini,1 Simona Mrakic-Sposta,3 Sarah Moretti,3 Manuela Monti,4 Ymera Pignochino,5 Silvia Benvenuti,5 Davide Prosperi,2,6 Giulia Stella,1 Patrizia Morbini,7 Federica Meloni8 1Clinic of Lung Diseases, IRCCS Foundation Policlinico San Matteo, Pavia, Italy; 2Deparment of Biotechnology and Bioscience, University of Milano - Bicocca, Milan, Italy; 3National Council of Research, Institute of Bioimaging and Molecular Physiology, Segrate, Milan, Italy; 4Laboratory of Biotechnology, Research Center of Rigenerative Medicine, IRCCS Foundation Policlinico San Matteo, Pavia, Italy; 5Experimental Clinical Molecular Oncology, IRCCS Candiolo Cancer Institute-FPO, Candiolo, Turin, Italy; 6Laboratory of Nanomedicine, Clinical Institute of Maugeri, S.p.A., Pavia, Italy; 7Department of Molecular Medicine, Pathology Unit, IRCCS Foundation Policlinico San Matteo, Pavia, Italy; 8Department of Internal Medicine, Pneumology Unit, University of Pavia, Pavia, Italy Purpose: Malignant pleural mesothelioma (MPM) is an aggressive tumor characterized by poor prognosis. Its incidence is steadily increasing due to widespread asbestos exposure. There is still no effective therapy for MPM. Pemetrexed (Pe) is one of the few chemotherapeutic agents approved for advanced-stage disease, although the objective response to the drug is limited. The use of gold nanoparticles (GNPs) as a drug delivery system promises several advantages, including specific targeting of malignant cells, with increased intracellular drug accumulation and reduced systemic toxicity, and, in the case of MPM, direct treatment administration into the pleural space. This study aims at exploring CD146 as a potential MPM cell-specific target for engineered Pe-loaded GNPs and to assess their effectiveness in inhibiting MPM cell line growth.Methods: MPM cell lines and primary cultures obtained by pleural effusions from MPM patients were assayed for CD146 expression by flow cytometry. Internalization by MPM cell lines of fluorescent dye-marked GNPs decorated with a monoclonal anti CD146 coated GNPs (GNP-HC) was proven by confocal microscopy. The effects of anti CD146 coated GNPs loaded with Pe (GNP-HCPe) on MPM cell lines were evaluated by cell cycle (flow cytometry), viability (MTT test), clonogenic capacity (soft agar assay), ROS production (electric paramagnetic resonance), motility (wound healing assay), and apoptosis (flow cytometry).Results: GNP-HC were selectively uptaken by MPM cells within 1 hour. MPM cell lines were blocked in the S cell cycle phase in the presence of GNP-HCPe. Both cell viability and motility were significantly affected by nanoparticle treatment compared to Pe. Apoptotic rate and ROS production were significantly higher in the presence of nanoparticles. Clonogenic capacity was completely inhibited following nanoparticle internalization.Conclusion: GNP-HCPe treatment displays in vitro antineoplastic action and is more effective than Pe alone in inhibiting MPM cell line malignant phenotype. The innovative use of specifically targeted GNPs opens the perspective of local intrapleural administration to avoid normal cell toxicity and enhance chemotherapy efficacy. Keywords: gold nanoparticles, nanodrug delivery, mesothelioma, pemetrexed, intrapleural deliveryCova EPandolfi LColombo MFrangipane VInghilleri SMorosini MMrakic-Sposta SMoretti SMonti MPignochino YBenvenuti SProsperi DStella GMorbini PMeloni FDove Medical PressarticleGold nanoparticlesnano-drug deliverymesotheliomapemetrexedintrapleural deliveryMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 773-785 (2019)